Arkadios Wealth Advisors Increases Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Arkadios Wealth Advisors lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 15.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,530 shares of the company’s stock after acquiring an additional 4,520 shares during the period. Arkadios Wealth Advisors owned approximately 0.08% of Omnicell worth $935,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in OMCL. Liontrust Investment Partners LLP acquired a new stake in shares of Omnicell in the second quarter valued at about $4,066,000. Louisiana State Employees Retirement System grew its position in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after purchasing an additional 228,093 shares during the period. Finally, Diversified Trust Co lifted its position in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after purchasing an additional 494 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Benchmark restated a “buy” rating and set a $38.00 target price on shares of Omnicell in a research note on Monday, July 15th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. upped their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Finally, Bank of America increased their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $37.83.

Omnicell Stock Performance

Shares of OMCL traded up $0.42 during mid-day trading on Friday, reaching $45.68. 5,657 shares of the company’s stock traded hands, compared to its average volume of 523,856. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $61.44. The stock has a market capitalization of $2.10 billion, a P/E ratio of -98.39, a price-to-earnings-growth ratio of 83.06 and a beta of 0.80. The business’s 50-day moving average price is $33.63 and its 200-day moving average price is $30.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities analysts predict that Omnicell, Inc. will post 0.36 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.